15. The pharmaceutical composition comprising a compound of formula I of claim 13, wherein the disease or disorder or condition is selected from the group classified or diagnosed as major or minor neurocognitive disorders, or disorders arising due to neurodegeneration.

~~16.~~ ~~The pharmaceutical composition comprising a compound of formula I of claim 13 comprising administering a compound of formula I, a tautomeric form, a stereoisomer, or a pharmaceutically acceptable salt thereof, in combination with or as adjunct to medications utilized in the treatment of attention deficit hyperactivity disorders, schizophrenia, cognitive disorders such as Alzheimer's disease, Parkinson's dementia, vascular dementia or dementia associated with Lewy bodies, or traumatic brain injury.~~

~~**17.**~~ ~~The pharmaceutical composition comprising a compound of formula I of claim 13 or 14, further comprising administering a compound of formula I, a tautomeric form, a stereoisomer, or a pharmaceutically acceptable salt thereof, in combination with or as an adjunct to acetylcholinesterase inhibitors, disease modifying drugs or biologics for neurodegenerative disorders, dopaminergic drugs, antidepressants, or a typical or an atypical antipsychotic.~~